Sanofi, Regeneron say rheumatoid arthritis drug Kevzara failed as COVID-19 treatment

More short articles on drug store: Mylan recalls 2 drugs after label mix-upNovartis establishes new sustainability goalsBayer to obtain vitamin subscription company for $225M.

Sanofi, in partnership with Regeneron, had actually been checking the drugs results against COVID-19 due to the fact that the drug is shown to curb swelling. The drug didnt significantly shorten clients medical facility remains in a research study including 420 people, Sanofi said..

Sanofis rheumatoid arthritis drug Kevzara has stopped working to treat COVID-19 in early medical trials, the drugmaker stated this week.

Sanofi CEO Paul Hudson has said Kevzara was a “long shot” as a treatment against COVID-19, according to Bloomberg..

Regeneron is also testing an antibody drug cocktail it has developed specifically for COVID-19.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Sanofi said patients were simply about as most likely to pass away and develop severe infections while on Kevzara as they were on a placebo..

Maia Anderson –
Wednesday, September 2nd, 2020
Print|Email.